13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Cell and mouse studies identified an ALK-targeting antibody-drug conjugate (ADC) that could help treat neuroblastoma. The ADC consists of an anti-ALK mAb linked to the generic chemotherapy drug thienoindole....
18:40 , Mar 12, 2019 |  BC Extra  |  Financial News

InventisBio raises $70M series C to advance early stage pipeline

InventisBio raised $70 million in a series C round led by Advantech Capital and CMBI, the Chinese biotech announced late Monday. Pudong Innotek and existing investors Lilly Asia Ventures and OrbiMed Asia also participated in...
18:59 , Jan 4, 2019 |  BC Week In Review  |  Company News

Betta Pharma signs China deals with InventisBio, Merus

InventisBio Inc. (Shanghai, China) granted Betta Pharmaceuticals Co. Ltd (SZSE:300558) exclusive rights to develop and commercialize D-0316 in China, including Hong Kong and Taiwan. InventisBio will receive an upfront payment and R&D milestones totaling RMB230...
16:42 , Oct 26, 2018 |  BC Week In Review  |  Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
18:23 , Oct 23, 2018 |  BC Extra  |  Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
16:42 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

Cancer company Beijing Jacobio Pharmaceutical Co. Ltd. (Beijing, China) raised $55 million in a series C round led by Qiming Venture Capital and Hillhouse Capital. Prudence Investment Management also participated. Jacobio's lead candidate JAB-3068, a...
23:58 , Sep 6, 2018 |  BioCentury  |  Finance

Jacobio’s ladder

Beijing Jacobio Pharmaceutical Co. Ltd. plans to use its $55 million series C round to fuel its creation of spinouts housing internally developed assets. Existing investor Qiming Venture Partners led the tranched round, which closed...
13:57 , Aug 31, 2018 |  BC Extra  |  Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

Cancer company Beijing Jacobio Pharmaceutical Co. Ltd. (Beijing, China) raised $55 million in a series C round led by Qiming Venture Capital and Hillhouse Capital. Prudence Investment Management also participated. Jacobio's lead candidate JAB-3068, a...
20:30 , Aug 17, 2018 |  BioCentury  |  Finance

Location, location, biotech

Chinese real estate investor Xuechao Wang placed a bet on a domestic cancer start up 16 years ago, which helped pave the way for the country’s first homegrown targeted cancer therapy. Now, market growth in...
19:02 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Patient sample and mouse studies suggest inhibiting the ALK - STING axis could help treat sepsis. In patient peripheral blood mononuclear cells (PBMCs), levels of ALK and STING were higher than in PBMCs...